In-Silico Investigation on Chloroquine Derivatives: A Potential Anti-COVID-19 Main Protease

dc.contributor.authorAdeoye, Moriam Dasola
dc.date.accessioned2026-02-26T14:17:51Z
dc.date.issued2022
dc.description.abstractSARS-CoV-2 (Covid 19) continues to be a great threat to lives globally as it causes illnesses such as the common cold, severe acute respiratory syndrome and spreads easily among people. In this work, thirteen molecular compounds were studied via quantum chemical calculations, molecular docking, and dynamic simulation, and ADMET (absorption, distribution, metabolism, excretion, and toxicity). The obtained descriptors (Log P, HBA, HBD, and molecular weight) showed that the studied compounds have the ability to act as a drug. Thus, it was detected that all the studied selected compounds possess a better tendency to inhibit main coronavirus protease; however, compound C1 has a higher tendency to inhibit main coronavirus protease than the other compounds, including the standard (Chloroquine). ADMET properties of compound C1 proved that the predicted ADMET level was better than the ADMET properties of the referenced drug.
dc.identifier.citationLatona, D. F., Mutiu, O. A., Adeoye, M. D., Oyebamiji, A. K., Akintelu, S. A. & Adedapo, A. S. (2022). In-Silico Investigation on Chloroquine Derivatives: A Potential Anti-COVID-19 Main Protease. Biointerface Research in Applied Chemistry, 12(6), 8492-8501
dc.identifier.urihttps://repository.fuo.edu.ng/handle/123456789/221
dc.language.isoen
dc.subjectchloroquine
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectmolecular dynamic simulation
dc.subjectDFT
dc.subjectdocking
dc.subjectADMET
dc.titleIn-Silico Investigation on Chloroquine Derivatives: A Potential Anti-COVID-19 Main Protease
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
In_Silico_Investigation_on_Chloroquine_D.pdf
Size:
284.97 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description: